What is Star Sports Medicine Co., Ltd.'s (1609.HK) StockRank?

MoatMap's StockRank for Star Sports Medicine Co., Ltd. (1609.HK) is 26/100, with a Sell signal. This is a composite score combining Quality (80), Value (12), and Momentum (25) factor ranks across MoatMap's 20,000+ stock universe.

Does Star Sports Medicine Co., Ltd. have an economic moat?

Star Sports Medicine Co., Ltd. (1609.HK) has a Quality factor score of 80/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Star Sports Medicine Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Star Sports Medicine Co., Ltd. (1609.HK) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Star Sports Medicine Co., Ltd. in?

Star Sports Medicine Co., Ltd. (1609.HK) operates in the Healthcare sector, specifically the Medical Devices industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

1609.HK

SELLREMOVE

Star Sports Medicine Co., Ltd. · Healthcare · China · $1.4B · Avg Vol: $2M/d

StockRank

P/E (TTM)

66.9x

ROE

25.3%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Star Sports Medicine lacks the scale, global distribution network, and regulatory moats of dominant medical device players, making it an unsuitable vehicle for high-conviction capital.

COMPANY DESCRIPTION

Star Sports Medicine Co., Ltd. develops, manufactures, and sells sports medicine medical devices, including implants, instruments, and biomaterials for joint reconstruction. The company's competitive advantage is its comprehensive product portfolio in a Chinese market historically dominated by foreign multinational brands. It is a high-growth medical device pioneer capitalizing on import substitution trends in China's orthopedic sector.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	19M	30M	42M	51M	40.1%
EPS	0.09	0.13	0.22	0.32	50.3%
Shares	55M	55M	55M	55M	0.0%
Debt	1M	1M	3M	4M	43.4%
Equity	42M	48M	60M	78M	22.9%
Op CF	7M	10M	12M	20M	41.2%
Inv CF	769,433	-3M	-47M	-15M	—
Fin CF	17M	3M	1M	-1M	—

PRICE (1M)-15.4%

$23.35

RSI (14)

29.9

SCORE BREAKDOWN

Quality

ROIC

24.4%94.7

ROE

25.3%92.6

GP/Assets

45.3%83.2

Op. Margin

7.5%60.3

FCF/Assets

3.9%65.6

Piotroski

—83.4

Int. Cover

50.0x91.5

D/E Ratio

0.03x78.1

Current Ratio

5.04x71.0

Value

P/E (TTM)

66.9x14.4

EV/EBITDA

52.5x6.4

P/FCF

2847.0x3.4

P/B

11.0x9.4

P/S

22.7x15.7

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

—N/A

SMA 50/200

—N/A

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.4B

P/E (Forward)

—

Gross Margin

74.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 1609.HK are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
1609.HK	Star Sports Medicine Co., Ltd.(you)	$1.4B	26	SELL
300633.SZ	SonoScape Medical Corp.	$1.3B	28	SELL
688626.SS	Xiangyu Medical Co.,Ltd	$1.2B	20	SELL
688575.SS	Shenzhen YHLO Biotech Co., Ltd.	$870M	26	SELL
0853.HK	MicroPort Scientific Corporation	$1.8B	22	SELL
688108.SS	Sino Medical Sciences Technology Inc.	$1.4B	36	HOLD
600055.SS	Beijing Wandong Medical Technology Co.,Ltd.	$1.3B	37	HOLD
2675.HK	Shenzhen Edge Medical Co Ltd	$2.7B	28	SELL
688161.SS	Shandong Weigao Orthopaedic Device Co., Ltd	$1.6B	39	HOLD
300143.SZ	INKON Life Technology Co., Ltd.	$1.1B	38	HOLD

Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.0%

Star Sports Medicine Co., Ltd. (1609.HK) — Stock Score Summary

Star Sports Medicine Co., Ltd. (1609.HK) has a MoatMap StockRank of 26/100 based on Quality (80/100), Value (12/100), and Momentum (25/100) factor scores. The current signal is SELL. Star Sports Medicine lacks the scale, global distribution network, and regulatory moats of dominant medical device players, making it an unsuitable vehicle for high-conviction capital.

Key Financial Metrics

Price	$23.35
Market Cap	$1.4B
P/E (TTM)	66.92
Price/Book	11.00
Return on Equity	25.3%
Return on Invested Capital	24.4%
Debt/Equity	3.21
Gross Margin	74.1%
Operating Margin	7.5%
Free Cash Flow	$486K

Star Sports Medicine Co., Ltd. operates in the Medical Devices industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Star Sports Medicine Co., Ltd.’s (1609.HK) StockRank?: MoatMap’s StockRank for Star Sports Medicine Co., Ltd. (1609.HK) is 26/100, with a Sell signal. It is a composite of Quality (80), Value (12), and Momentum (25) factor ranks across MoatMap’s 20,000+ stock universe.
Does Star Sports Medicine Co., Ltd. have an economic moat?: Star Sports Medicine Co., Ltd. (1609.HK) has a Quality factor score of 80/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Star Sports Medicine Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Star Sports Medicine Co., Ltd. (1609.HK) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Star Sports Medicine Co., Ltd. in?: Star Sports Medicine Co., Ltd. (1609.HK) operates in the Healthcare sector, specifically the Medical Devices industry (China).